Medicine and Dentistry
Imiquimod
100%
Oral Cancer
100%
Clinical Trial
100%
Monotherapy
100%
Mouth Squamous Cell Carcinoma
42%
Neoplasm
28%
Necrosis
14%
Overall Survival
14%
Distant Metastasis
14%
Lymph Node
14%
Survival Rate
14%
Tumor Cell
14%
Adverse Event
14%
Prognostication
14%
Topical Treatment
14%
Recurrent Disease
14%
Programmed Cell Death
14%
Five-Year Survival Rate
14%
Metastatic Carcinoma
14%
Toll Like Receptor Agonist
14%
Immune Response
14%
Malignant Neoplasm
14%
Immunofluorescence
14%
Diseases
14%
Melanoma
14%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Mouth Cancer
100%
Clinical Trial
100%
Imiquimod
100%
Mouth Squamous Cell Carcinoma
42%
Neoplasm
42%
Survival Rate
28%
Overall Survival
14%
Malignant Neoplasm
14%
Recurrent Disease
14%
Necrosis
14%
Adverse Event
14%
Melanoma
14%
Toll Like Receptor Agonist
14%
Distant Metastasis
14%
Diseases
14%